tbuckley/cabot-search huggingface dataset:
Endoscopic submucosal dissection versus surgery for undifferentiated-type early gastric cancer: A meta-analysis.
Authors: Byung-Wook Kim, Dae Won Ma, Joon Sung Kim
Journal: Journal of Clinical Oncology (2019)

111 Background: It is still controversial to treat undifferentiated early gastric cancer by endoscopic submucosal dissection (ESD). Therefore, we aimed to perform a meta-analysis to investigate long-term outcomes of ESD and surgery for undifferentiated early gastric cancer. Methods: PubMed, Cochran Library, and EMBASE were used to search for relevant researches comparing endoscopic submucosal dissection and surgery for undifferentiated early gastric cancer. The methodological quality of the included publications was evaluated using the Risk of Bias Assessment tool for Non-randomized Studies. The overall survival rate, recurrence rate, adverse event rate, and complete resection rate were explored, and the odds ratio (OR) and 95% confidence interval (CI) were estimated. Results: This meta-analysis enrolled five studies, with 376 and 1148 participants undergoing ESD and surgery, respectively. Overall survival rate did not show significant difference between ESD and surgery group (OR 0.57, 95% CI 0.18 – 1.83, P = 0.34). However, ESD was associated with higher recurrence rate (OR 11.57, 95% CI 5.07 – 26.39, P &lt; 0.001) and lower complete resection rate (OR 0.03, 95% CI 0.01 – 0.11, P &lt; 0.001). Adverse event rate was similar between two groups (OR 0.95, 95% CI 0.46 – 1.96, P = 0.88). Conclusions: Despite higher recurrence rate and lower complete resection rate, ESD demonstrated similar overall survival rate and adverse event rate in the treatment of undifferentiated early gastric cancer compared to surgery.
Abstract 14825: Selenoprotein P Promotes the Development of Pulmonary Arterial Hypertension -A Possible Novel Therapeutic Target-
Authors: Nobuhiro Kikuchi, Kimio Satoh, Ryo Kurosawa, Nobuhiro Yaoita, Md. Elias-Al-Mamun, Mohammad Abdul Hai Siddique, Junichi Omura, Taijyu Satoh, Masamichi Nogi, Shinichiro Sunamura, Satoshi Miyata, Yoshiro Saito, Yasushi Hoshikawa, Yoshinori Okada, Hiroaki Shimokawa
Journal: Circulation (2017)

Background: Pulmonary arterial hypertension (PAH) is characterized by excessive proliferation of pulmonary artery smooth muscle cells (PASMCs). Methods & Results: To explore a novel therapeutic tar...
Temporal and Spatially Regulated Oncogenic KIT Expression and Loss of Dnmt3a Cooperate to Drive MPN Development: Role of PI3Kinase in Dnmt3a Loss Induced Hyperproliferation in Myeloid Cells
Authors: Lakshmi Reddy Palam, Baskar Ramdas, Sridhar reddy Srivatsan, Sarath Chandra Janga, Axel Roers, Alexander Gerbaulet, Reuben Kapur
Journal: Blood (2018)
Tissue Factor Pathway Inhibitor Enhances Transendothelial Migration of Chronic Lymphocytic Leukemia Cells through Binding to Glypican-3
Authors: Xueyan Cui, Geir Erland Tjønnfjord, Sandip Kanse, Nina Iversen, Anders EA Dahm, Christiane Filion Myklebust, Ling Sun, Zhong Xing Jiang, Mitchell Ho, Per Morten Sandset
Journal: Blood (2018)
Gastroschisis and Autism—Dual Canaries in the Californian Coalmine
Authors: Albert Stuart Reece, Gary Kenneth Hulse
Journal: JAMA Surgery (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Abstract 20501: Cardiac Regeneration in Mammalian Nonischemic Heart Failure
Authors: Yuan-Hung Liu, Ling-Ping Lai, Yi-Shuan Lin, Jiunn-Lee Lin
Journal: Circulation (2017)

The massive loss of cardiomyocytes after myocardial injury often results in cardiac fibrosis, chamber dilatation and heart failure. Using lineage tracing analysis, we recently confirmed that Nkx2.5 cardiac progenitor cells contributed directly to postnatal cardiomyogenesis after experimental myocardial infarction. However, whether cardiac progenitors participate in cardiomyogenesis in non-ischemic heart failure is not clear. To create an animal model of non-ischemic heart failure, we designed a genetic cardiomyocyte-depletion model by interbreeding α myosin heavy chain-Mer-Cre-Mer and ROSA-DTA mice. After the animal received low dose tamoxifen i.p. injection, one third of the mice died within one week. By analyzing LacZ staining of mice heart sections 4 weeks post 4-OH tamoxifen injection in cardiomyocyte depletion group (αMHC-MerCreMer/R26R-LacZ/ ROSA-DTA) and cardiomyocyte non-depletion control group (αMHC-MerCreMer /R26R-LacZ), we confirmed about 30% of cardiomyocytes were depleted by Diphtheria toxin ...
Leveraging decision consistency to decompose suboptimality in terms of its ultimate predictability
Authors: Valentin Wyart
Journal: Behavioral and Brain Sciences (2018)

Although the suboptimality of perceptual decision making is indisputable in its strictest sense, characterizing the nature of suboptimalities constitutes a valuable drive for future research. I argue that decision consistency offers a rarely measured, yet important behavioral metric for decomposing suboptimality (or, more generally, deviations from any candidate model of decision making) into ultimately predictable and inherently unpredictable components.
Subgroup analysis of JCOG0501 phase III study to confirm superiority of additional neoadjuvant chemotherapy with S-1 plus cisplatin to D2 gastrectomy with S-1 adjuvant chemotherapy for resectable type IV or large type III gastric cancer.
Authors: Hitoshi Katai, Yoshiaki Iwasaki, Masanori Terashima, Junki Mizusawa, Hiroshi Katayama, Kenichi Nakamura, Takaki Yoshikawa, Narikazu Boku, Takanobu Yamada, Tsuneaki Fujiya, Yoshiyuki Kawashima, Takahiro Kinoshita, Manabu Ohashi, Hiroki Yamaue, Takeshi Sano, Mitsuru Sasako
Journal: Journal of Clinical Oncology (2019)

110 Background: We previously reported that the superiority of neoadjuvant chemotherapy (NAC) with S-1 plus cisplatin was not demonstrated for schirrhous or similar macroscopic type (type 4 or large type 3) gastric cancer. However, overall survival (OS) in both arms was better than previous reports (3-year OS: 62.4% in gastrectomy plus adjuvant S-1 [arm A] and 60.9% in NAC followed by gastrectomy plus adjuvant S-1 [arm B]). Therefore, we explored whether histology and peritoneal cytology are associated with treatment effect. Methods: After staging laparoscopy, a total of 300 eligible patients with clinically resectable disease were randomized to arm A, or arm B. In this report, treatment effect was explored in key subgroups such as histology and peritoneal cytology using the data from JCOG0501. Cox regression model was used to investigate the interaction between arms and subgroups. Results: Hazard ratio (HR) classified by histology (excluding one missing) was 0.686 (95% CI: 0.414-1.138) for non-signet type (n = 123) and 1.158 (95% CI: 0.805-1.666) for signet type (n = 176) (p = 0.098 for interaction). HR by peritoneal cytology was 0.870 (95%CI: 0.616-1.228) for the negative (n = 240) and 1.051 (95% CI: 0.598-1.845) for the positive (n = 60) (p = 0.513 for interaction). 3 year-OS of signet ring cell histology was 63.2% (95% CI: 52.2-72.4) in arm A and 51.7% (95% CI: 40.9-61.5) in arm B, that of non-signet ring cell histology was 62.3% (95% CI: 48.9-73.1) in arm A and 74.2% (95% CI: 61.4-83.3) in arm B, and that of peritoneal cytology positive was 35.7% (95% CI: 18.9-53.0) in arm A and 25.0% in arm B (95% CI: 11.8-40.7), and that of peritoneal cytology negative was 68.6% (95% CI: 59.5-76.1) in arm A and 70.6% (95% CI: 61.5-77.9) in arm B. Conclusions: NAC might be beneficial for non-signet ring cell histology. Considering the survival results, primary surgery followed by S-1 could be recommended for this disease even though histology was signet ring cell type or peritoneal cytology was positive. Clinical trial information: UMIN000000279.
Treatment with 2,4-Dihydroxybenzoic Acid Prevents FSGS Progression and Renal Fibrosis in Podocyte-Specific Coq6 Knockout Mice
Authors: Eugen Widmeier, Merlin Airik, Hannah Hugo, David Schapiro, Johannes Wedel, Chandra C. Ghosh, Makiko Nakayama, Ronen Schneider, Agape M. Awad, Anish Nag, Jang Cho, Markus Schueler, Catherine F. Clarke, Rannar Airik, Friedhelm Hildebrandt
Journal: Journal of the American Society of Nephrology (2019)

Although studies have identified >55 genes as causing steroid-resistant nephrotic syndrome (SRNS) and localized its pathogenesis to glomerular podocytes, the disease mechanisms of SRNS remain largely enigmatic. We recently reported that individuals with mutations in COQ6, a coenzyme Q (also called CoQ10, CoQ, or ubiquinone) biosynthesis pathway enzyme, develop SRNS with sensorineural deafness, and demonstrated the beneficial effect of CoQ for maintenace of kidney function.To study COQ6 function in podocytes, we generated a podocyte-specific Coq6 knockout mouse (Coq6podKO ) model and a transient siRNA-based COQ6 knockdown in a human podocyte cell line. Mice were monitored for development of proteinuria and assessed for development of glomerular sclerosis. Using a podocyte migration assay, we compared motility in COQ6 knockdown podocytes and control podocytes. We also randomly assigned 5-month-old Coq6podKO mice and controls to receive no treatment or 2,4-dihydroxybenzoic acid (2,4-diHB), an analog of a CoQ precursor molecule that is classified as a food additive by health authorities in Europe and the United States.Abrogation of Coq6 in mouse podocytes caused FSGS and proteinuria (>46-fold increases in albuminuria). In vitro studies revealed an impaired podocyte migration rate in COQ6 knockdown human podocytes. Treating Coq6podKO mice or cells with 2,4-diHB prevented renal dysfunction and reversed podocyte migration rate impairment. Survival of Coq6podKO mice given 2,4diHB was comparable to that of control mice and significantly higher than that of untreated Coq6podKO mice, half of which died by 10 months of age.These findings reveal a potential novel treatment strategy for those cases of human nephrotic syndrome that are caused by a primary dysfunction in the CoQ10 biosynthesis pathway.
Comparison of Chimeric Antigen Receptor T Cells from Allogenic or Autologous Sources in Patients with Acute Lymphoblastic Leukemia
Authors: Yongxian Hu, Jiasheng Wang, Yanlei Zhang, Guoqing Wei, Huijun Xu, Wenjun Wu, Jian Yu, Yi Luo, Jimin Shi, Shaohui Liu, Kangyan Wang, Zhenxing Guo, Alex HONGSHENG Chang, He Huang
Journal: Blood (2018)
Diagnosis and Management of Infectious Diarrhea
Authors: Keith W. Hamilton, Adam S. Cifu
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
AML Xenografts Undergo Extensive Clonal Competition and Unmask Rare Clones in Patient Samples
Authors: Carl Sandén, Henrik Lilljebjörn, Christina Orsmark-Pietras, Karim Saba, Carl Högberg, Marianne Rissler, Vladimir Lazarevic, Gunnar Juliusson, Helena Ågerstam, Thoas Fioretos
Journal: Blood (2018)
Glial Cell Line–Derived Neurotrophic Factor Enhances Autophagic Flux in Mouse and Rat Hepatocytes and Protects Against Palmitate Lipotoxicity
Authors: Simon Musyoka Mwangi, Ge Li, Lan Ye, Yunshan Liu, Francois Reichardt, Samantha M. Yeligar, C. Michael Hart, Mark J. Czaja, Shanthi Srinivasan
Journal: Hepatology (2019)

Glial cell line–derived neurotrophic factor (GDNF) is a protein that is required for the development and survival of enteric, sympathetic, and catecholaminergic neurons. We previously reported that GDNF is protective against high fat diet (HFD)‐induced hepatic steatosis in mice through suppression of hepatic expression of peroxisome proliferator activated receptor‐γ and genes encoding enzymes involved in de novo lipogenesis. We also reported that transgenic overexpression of GDNF in mice prevented the HFD‐induced liver accumulation of the autophagy cargo‐associated protein p62/sequestosome 1 characteristic of impaired autophagy. Here we investigated the effects of GDNF on hepatic autophagy in response to increased fat load, and on hepatocyte mitochondrial fatty acid β‐oxidation and cell survival. GDNF not only prevented the reductions in the liver levels of some key autophagy‐related proteins, including Atg5, Atg7, Beclin‐1 and LC3A/B‐II, seen in HFD‐fed control mice, but enhanced their levels after 12 weeks of HFD feeding. In vitro , GDNF accelerated autophagic cargo clearance in primary mouse hepatocytes and a rat hepatocyte cell line, and reduced the phosphorylation of the mechanistic target of rapamycin complex downstream‐target p70S6 kinase similar to the autophagy activator rapamycin. GDNF also enhanced mitochondrial fatty acid β‐oxidation in primary mouse and rat hepatocytes, and protected against palmitate‐induced lipotoxicity. Conclusion : We demonstrate a role for GDNF in enhancing hepatic autophagy and in potentiating mitochondrial function and fatty acid oxidation. Our studies show that GDNF and its receptor agonists could be useful for enhancing hepatocyte survival and protecting against fatty acid–induced hepatic lipotoxicity.
Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase <scp>III</scp> clinical trials
Authors: A. Blauvelt, D. Rosmarin, T. Bieber, E.L. Simpson, J. Bagel, M. Worm, M. Deleuran, N. Katoh, M. Kawashima, B. Shumel, Z. Chen, A.B. Rossi, T. Hultsch, M. Ardeleanu
Journal: British Journal of Dermatology (2019)
Palliative Care for Patients With Opioid Misuse—Reply
Authors: Yael Schenker, Jessica S. Merlin, Timothy Quill
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 21169: Abnormal Left Atrial Mechanics Associate With Embolic Events in Light-Chain Cardiac Amyloidosis
Authors: Roberta Mussinelli, Graham Lohrmann, Stefano Perlini, Vaishali Sanchorawala, Frederick L Ruberg, Deepa M Gopal
Journal: Circulation (2017)

Introduction: Cardioembolic events are common in cardiac amyloidosis (CA) in the absence of atrial fibrillation. In sinus rhythm (SR), marked reduction in the atrial component of left ventricular filling confers a physiology of atrial electromechanical disassociation (EMD), an entity well-recognized in CA. Presently, there are no effective tools to predict risk for atrial EMD. Hypothesis: We hypothesized that detection of blunted left atrial (LA) mechanics by strain imaging would provide increased sensitivity to detect abnormal LA contraction mechanics and associate with embolic events/intracardiac thrombus among CA patients in SR. Methods: Baseline echocardiograms were analyzed for LA strain (TomTec, Unterschleissheim, Germany) from a retrospectively identified cohort of n=46 CA patients, of whom n=17 developed an embolic event/intercardiac thrombus (event+) and n=29 did not (event-). Patients with prior/active atrial fibrillation or flutter or administration of anticoagulation were excluded by electrocardiographic or medical record review. Comparisons between groups applied Student’s t test utilizing equal variance assumption testing. Results: No significant differences were identified in standard structural echocardiographic parameters (between event+ vs. event- groups), including LVEF (44 vs. 50%, p=0.11), transmitral A velocity (51 vs. 49 cm/s, p=0.84), LA volume index (41 vs. 40 mL/m 2 , p=0.77), and diastolic dysfunction grade (Grade III in 47 vs. 52%, p=0.53). In patients with light-chain CA, LA contraction mechanics were significantly decreased among event+ persons compared to event- persons (Figure). Conclusions: LA contraction mechanics are significantly blunted in light-chain CA patients who experienced an embolic event/intracardiac thrombus despite normal SR. These data suggest that LA strain assessment may afford a means to guide anticoagulation treatment in high-risk CA patients.
Early stage hepatocellular carcinoma treated with stereotactic body radiation therapy: A pooled analysis from two North American institutions.
Authors: Ashwathy Susan Mathew, Eshetu G. Atenafu, Dawn Owen, Chris Maurino, Anthony M. Brade, James D. Brierley, Robert Edward Dinniwell, John Kim, Charles Cho, Jolie Ringash, Rebecca Wong, Kyle Clifford Cuneo, Mary Uan-Sian Feng, Theodore Steven Lawrence, Laura A. Dawson
Journal: Journal of Clinical Oncology (2019)

350 Background: To report outcomes of pooled data from patients with early stage hepatocellular carcinoma (HCC) treated with stereotactic body radiation therapy (SBRT) at two North American Institutions. Methods: An IRB approved collaborative review of patients with HCC treated with radical intent SBRT was conducted. Inclusion criteria included patients with Stage I-IIIA HCC (UICC/AJCC 7th Ed.) treated with SBRT (≥ 4.5 Gy/ fraction) from June 2003 until Dec 2016. Patients who were treated with SBRT were ineligible for resection, percutaneous ablative or hepatic intravascular therapies. Patients with vascular invasion and those treated with palliative intent (e.g. HCC rupture) were excluded. Overall survival, local control and toxicity of treatment were reviewed retrospectively. Results: Of 310 eligible patients, 23% were Child-Pugh (CP) class B/C (21%/2%), and 40% had failed prior liver directed therapies. The median HCC diameter was 2.4 cm (range 0.5-18.1 cm), and the median prescribed dose was 39 Gray (Gy) in 5 fractions (range: 14 - 60 Gy in 2-6 fractions). Median BED was 78.75 Gy (Range: 23.8-180.0 Gy). 8.4% of patients underwent liver transplant after SBRT. Local control at 1, 3 and 5 years was 91.5%, 82.6% and 82.6%. On multivariable analysis (MVA), the use of breath-hold motion management, but not T stage, size or dose, was significantly associated with local control (p = 0.0098). The 1, 3, and 5 year overall survival (OS) was 77.3%, 37.9% and 23.5%. Factors associated with improved OS on MVA included baseline CP A score (HR = 0.58, p &lt; 0.0045), AFP &lt; 10 µg/L (HR = 0.66, p = 0.0094), and transplant post SBRT (HR = 0.05, p &lt; 0.0001). The median survival of CP A vs. B/C patients was 30.3 and 17.6 months respectively. CTCAE (v4.0) grade 3 or higher luminal gastrointestinal organ toxicity occurred in 2.5% of patients, while a decline in CP score ≥ 2 points was seen in 16.7% of patients at 3 months post SBRT. Grade 3 and above elevated liver enzymes were seen in 12.6% and 8.1% of patients at baseline and at 3 months post SBRT. Conclusions: Similar to Asian series, this North American pooled analysis found high sustained local control and excellent survival in patients with early stage HCC treated with SBRT.
Association of the coronary artery disease risk gene GUCY1A3 with ischaemic events after coronary intervention
Authors: Thorsten Kessler, Bernhard Wolf, Niclas Eriksson, Daniel Kofink, Bakhtawar K Mahmoodi, Himanshu Rai, Vinicius Tragante, Axel Åkerblom, Richard C Becker, Isabell Bernlochner, Roman Bopp, Stefan James, Hugo A Katus, Katharina Mayer, Matthias Munz, Francesco Nordio, Michelle L O’Donoghue, Hendrik B Sager, Dirk Sibbing, Linda Solakov, Robert F Storey, Jana Wobst, Folkert W Asselbergs, Robert A Byrne, Jeanette Erdmann, Wolfgang Koenig, Karl-Ludwig Laugwitz, Jurrien M ten Berg, Lars Wallentin, Adnan Kastrati, Heribert Schunkert
Journal: Cardiovascular Research (2019)

A common genetic variant at the GUCY1A3 coronary artery disease locus has been shown to influence platelet aggregation. The risk of ischaemic events including stent thrombosis varies with the efficacy of aspirin to inhibit platelet reactivity. This study sought to investigate whether homozygous GUCY1A3 (rs7692387) risk allele carriers display higher on-aspirin platelet reactivity and risk of ischaemic events early after coronary intervention.The association of GUCY1A3 genotype and on-aspirin platelet reactivity was analysed in the genetics substudy of the ISAR-ASPI registry (n = 1678) using impedance aggregometry. The clinical outcome cardiovascular death or stent thrombosis within 30 days after stenting was investigated in a meta-analysis of substudies of the ISAR-ASPI registry, the PLATO trial (n = 3236), and the Utrecht Coronary Biobank (n = 1003) comprising a total 5917 patients. Homozygous GUCY1A3 risk allele carriers (GG) displayed increased on-aspirin platelet reactivity compared with non-risk allele (AA/AG) carriers [150 (interquartile range 91-209) vs. 134 (85-194) AU⋅min, P < 0.01]. More homozygous risk allele carriers, compared with non-risk allele carriers, were assigned to the high-risk group for ischaemic events (>203 AU⋅min; 29.5 vs. 24.2%, P = 0.02). Homozygous risk allele carriers were also at higher risk for cardiovascular death or stent thrombosis (hazard ratio 1.70, 95% confidence interval 1.08-2.68; P = 0.02). Bleeding risk was not altered.We conclude that homozygous GUCY1A3 risk allele carriers are at increased risk of cardiovascular death or stent thrombosis within 30 days after coronary stenting, likely due to higher on-aspirin platelet reactivity. Whether GUCY1A3 genotype helps to tailor antiplatelet treatment remains to be investigated.